Inhaled no and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension acute effects on postoperative gas exchange and hemodynamics

Circulation: Heart Failure

Volumn 5, Issue 1, 2012, Pages 47-53

  Matamis, Dimitrios ^a   Pampori, Smaro ^a   Papathanasiou, Athanasios ^a,b   Papakonstantinou, Panagiota ^a   Tsagourias, Mathew ^a   Galiatsou, Eftichia ^a,b   Koulouras, Vasilios ^a,b   Nakos, George ^a,b  

^a PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Cardiac surgery; Heart failure; Nitric oxide; Pulmonary hypertension; Sildenafil

Indexed keywords

NITRIC OXIDE; SILDENAFIL; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; VASODILATOR AGENT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART INDEX; HEART VALVE REPLACEMENT; HUMAN; HYPOXEMIA; LUNG ARTERY PRESSURE; LUNG GAS EXCHANGE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE; VENOUS OXYGEN TENSION; AGED; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; HEART SURGERY; HEMODYNAMICS; HYPERTENSION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; VASCULAR RESISTANCE;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AGED; BLOOD PRESSURE; CARDIAC SURGICAL PROCEDURES; DRUG THERAPY, COMBINATION; FEMALE; HEART VALVE DISEASES; HEMODYNAMICS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; PIPERAZINES; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; PULMONARY GAS EXCHANGE; PURINES; RETROSPECTIVE STUDIES; SULFONES; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 84859628936     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.963314     Document Type: Article

References (28)

1. Trachte AL, Lobato EB, Urdaneta F, Hess PJ, Klodell CT, Martin TD, Staples ED, Beaver TM. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg. 2005;79:194-197; discussion 194-197. (Pubitemid 40037471)
2. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Moliterno DJ, Mukherjee D, Pohost GM, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119:2250-2294.
3. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Al Attar N, Andreotti F, Aschermann M, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L, Kitsiou AN, Lang I, Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Domenech MT, Vonk-Noordegraaf A, Zamorano JL. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-2537.
4. Hoeper MM, Rubin LJ. Update in pulmonary hypertension 2005. Am J Respir Crit Care Med. 2006;173:499-505.
5. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173-1174.
6. Loh E, Stamler JS, Hare JM, Loscalzo J, Colucci WS. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation. 1994;90:2780-2785.
7. Fullerton DA, McIntyre RC Jr. Inhaled nitric oxide: Therapeutic applications in cardiothoracic surgery. Ann Thorac Surg. 1996;61:1856-1864. (Pubitemid 26179757)
8. Adatia I, Perry S, Landzberg M, Moore P, Thompson JE, Wessel DL. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. J Am Coll Cardiol. 1995;25: 1656-1664.
9. Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun. 2005;334:930-938. (Pubitemid 41033209)
10. Klodell CT Jr, Morey TE, Lobato EB, Aranda JM Jr, Staples ED, Schofield RS, Hess PJ, Martin TD, Beaver TM. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg. 2007; 83:68-71; discussion 71. (Pubitemid 44917910)
11. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: Combined administration with inhaled nitric oxide. Chest. 2005;127:1647-1653. (Pubitemid 46218790)
12. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007;115:59-66. (Pubitemid 46058612)
13. Fung E, Fiscus RR, Yim AP, Angelini GD, Arifi AA. The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest. 2005;128:3065-3073. (Pubitemid 41507668)
14. Ockaili R, Salloum F, Hawkins J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol. 2002;283: H1263-H1269.
15. Tawakol A, Aziz K, Migrino R, Watkowska J, Zusman R, Alpert NM, Fischman AJ, Gewirtz H. Effects of sildenafil on myocardial blood flow in humans with ischemic heart disease. Coron Artery Dis. 2005;16: 443-449. (Pubitemid 41527452)
16. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243-2278.
17. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation. 1991;83:2038-2047.
18. Melenovsky V, Al-Hiti H, Kazdova L, Jabor A, Syrovatka P, Malek I, Kettner J, Kautzner J. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: The effects of sildenafil. J Am Coll Cardiol. 2009;54: 595-600.
19. Lindman BR, Chakinala MM. Modulating the nitric oxide: Cyclic GMP pathway in the pressure-overloaded left ventricle and group ii pulmonary hypertension. Int J Clin Pract Suppl. 2010;64:15-22.
20. Piggott LA, Hassell KA, Berkova Z, Morris AP, Silberbach M, Rich TC. Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments. J Gen Physiol. 2006;128:3-14. (Pubitemid 43967547)
21. Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995;25:1143-1153.
22. Siobal MS. Pulmonary vasodilators. Respir Care. 2007;52:885-899.
23. Zakliczynski M, Maruszewski M, Pyka L, Trybunia D, Nadziakiewicz P, Przybylski R, Zembala M. Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates. Transplant Proc. 2007;39:2856-2858. (Pubitemid 350088099)
24. Shim JK, Choi YS, Oh YJ, Kim DH, Hong YW, Kwak YL. Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery. J Thorac Cardiovasc Surg. 2006;132:1420-1425. (Pubitemid 44820235)
25. Cohen AH, Hanson K, Morris K, Fouty B, McMurty IF, Clarke W, Rodman DM. Inhibition of cyclic 3-5-guanosine monophosphatespecific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest. 1996;97:172-179.
26. Preston IR, Klinger JR, Houtches J, Nelson D, Farber HW, Hill NS. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med. 2005;99:1501-1510. (Pubitemid 41683931)
27. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403. (Pubitemid 34556392)
28. Gudmundsdottir IJ, McRobbie SJ, Robinson SD, Newby DE, Megson IL. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation. Biochem Biophys Res Commun. 2005;337:382-385. (Pubitemid 41393806)